Zealand Pharma

Director's Dealing • Dec 2, 2015

Copenhagen, 2015-12-02 15:51 CET (GLOBE NEWSWIRE) -- 2 December 2015 – Pursuant
to the Danish Securities Trading Act, section 28a, Zealand disclose information
on transactions with the company’s shares and related securities by executives
and persons/companies closely related to them.

With reference to the above, Zealand announces it has received information on
the below transactions for disclosure. The transactions relate to the exercise
of employee warrants at an exercise price of DKK 94.60 per warrant as announced
on 4 November 2015 (Company announcement no. 47-15) and DKK 77.00 per warrant
as announced on 19 November 2015 (Report of executives transactions no. 5-15),
respectively. The transactions reported today are to finance the warrant
exercise and to pay taxes on the exercise, which according to Danish tax rules
become due immediately upon exercise.

Name: Christian Thorkildsen

Reason: Employee elected member of the Board of Directors

Issuer: Zealand Pharma A/S

Designation: Shares

ISIN Code: DK0060257814

Transaction: Sale of shares

Trading Date: 30 November 2015

Market: Nasdaq Copenhagen

Number: 4,000

Price: DKK 148.00

Total value: DKK 592,000.00

Following the transaction, Christian Thorkildsen holds 15,000 shares and 32,000
warrants in Zealand.

Name: Jens Peter Stenvang

Reason: Employee elected member of the Board of Directors

Issuer: Zealand Pharma A/S

Designation: Shares

ISIN Code: DK0060257814

Transaction: Sale of shares

Trading Date: 1 December 2015

Market: Nasdaq Copenhagen

Number: 1,000

Price: DKK 150.08

Total value: DKK 150,080.00

Following the transaction, Jens Peter Stenvang holds 1,000 shares and 6,500
warrants in Zealand.

Name: Mats Blom

Reason: Senior Vice President and Chief Financial Officer

Issuer: Zealand Pharma A/S

Designation: Shares

ISIN Code: DK0060257814

Transaction: Sale of shares

Trading Dates: 1 and 2 December 2015

Market: Nasdaq Copenhagen

Number: 8,057

Price: DKK 150.02

Total value: DKK 1,208,711.14

Following the transaction, Mats Blom holds 110,000 shares and 137,038 warrants
in Zealand.

                                  ?????

For further information, please contact:

Hanne Leth Hillman, Senior Vice President , Investor Relations and
Communications

Tel: +45 50 60 36 89, email: hlh@zealandpharma.com

About Zealand Pharma

Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (“Zealand”) is a biotech company
with leading-edge scientific expertise in turning peptides into medicines.
Zealand has a growing proprietary pipeline of novel specialty drug candidates
and a mature portfolio of products and projects under license collaborations
with Sanofi, Helsinn Healthcare and Boehringer Ingelheim.

Zealand’s first invented medicine, lixisenatide, a once-daily prandial GLP-1
analogue for the treatment of Type 2 diabetes, is marketed globally outside the
US as Lyxumia® by Sanofi and under regulatory review in the US. The license
collaboration with Sanofi covers also a single-product combination of
lixisenatide and insulin glargine (Lantus®) which is on track for regulatory
submission in the US in Q4 2015 and in the European Union in Q1 2016.

The proprietary pipeline includes; danegaptide for ischemic reperfusion
Injuries in Phase II development; ZP1848 for Short Bowel Syndrome in Phase II
development; and the stable glucagon analogue, ZP4207, in Phase II preparation
both as a single-dose rescue pen for severe hypoglycemia and for multiple-dose
use to treat and control mild to moderate hypoglycemia; as well as several
preclinical peptide therapeutics.

The company is based in Copenhagen (Glostrup), Denmark. For further information
about Zealand’s business and activities, please visit: www,zealandpharma.com or
follow us on Twitter @ZealandPharma